Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Upadacitinib may cause hair loss.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Many patients on new leukemia drugs had mild to moderate skin reactions.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Tofacitinib effectively treats Alopecia Areata.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Ritlecitinib is safe and may effectively treat alopecia areata.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.